Healixa Valuation
| EMOR Stock | USD 0.06 0.01 18.00% |
Healixa seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Healixa from evaluating the firm fundamentals such as shares outstanding of 77.99 M as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Healixa's price fluctuation is out of control at this time. Calculation of the real value of Healixa is based on 3 months time horizon. Increasing Healixa's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Healixa pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Healixa. Since Healixa is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Healixa Pink Sheet. However, Healixa's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.059 | Real 0.0565 | Hype 0.06 | Naive 0.0565 |
The intrinsic value of Healixa's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Healixa's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Healixa helps investors to forecast how Healixa pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Healixa more accurately as focusing exclusively on Healixa's fundamentals will not take into account other important factors: Healixa Total Value Analysis
Healixa is currently estimated to have valuation of 0 with market capitalization of 15.6 M, debt of , and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Healixa fundamentals before making equity appraisal based on enterprise value of the companyHealixa Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Healixa connotes not a very effective usage of assets in November.About Healixa Valuation
The pink sheet valuation mechanism determines Healixa's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Healixa based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Healixa. We calculate exposure to Healixa's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Healixa's related companies.Healixa Inc. operates as a technology company with assets in both healthtech and fintech. The company was founded in 1977 and is based in Holbrook, New York. Healixa operates under Health Information Services classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Healixa's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Healixa's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Healixa's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Healixa's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Healixa's revenue streams: Identify Healixa's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Healixa's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Healixa's growth potential: Evaluate Healixa's management, business model, and growth potential.
- Determine Healixa's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Healixa's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Healixa Pink Sheet Analysis
When running Healixa's price analysis, check to measure Healixa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Healixa is operating at the current time. Most of Healixa's value examination focuses on studying past and present price action to predict the probability of Healixa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Healixa's price. Additionally, you may evaluate how the addition of Healixa to your portfolios can decrease your overall portfolio volatility.